Clinical efficacy of therapy with all-trans retinoic acid in patients with severe fever with thrombocytopenia syndrome

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300076238

Enrollment

Unknown

Registered

2023-09-28

Start date

2023-09-30

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe fever with thrombocytopenia syndrome

Interventions

Control group:Symptomatic treatment

Intervention group:Symptomatic treatment+All-trans retinoic acid treatment

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with SFTS through laboratory testing. The time from onset to hospitalization of the patient is less than 7 days.

Exclusion criteria

Exclusion criteria: 1. Aged 6*ULN; AST > 20*ULN; ALT > 20*ULN; ALP > 20*ULN; Total bilirubin > 10*ULN; 5. Patients with deep vein thrombosis or pulmonary embolism within six months; 6. Subject unwilling or unable to follow protocol procedures.

Design outcomes

Primary

Measure	Time frame
The 28-day case fatality rate of SFTS;	—

Secondary

Measure	Time frame
inflammatory cytokines;PLT and WBC;Hepatorenal function;Lymphocyte subpopulation;Viral load of SFTSV;Incidence of 28-day multiple organ failure;The time course of resolution of the main symptoms of SFTS;	—

Countries

China

Contacts

Public ContactLiu Wei

Beijing Institute of Microbiology and Epidemiology

lwbime@163.com+86 10 6694 8499

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026